PSMA Radioligand Therapy | Advances in Prostate Cancer Treatments | Part 2
Published Date: March 24, 2022
Response rates to Lutetium PSMA treatments are good, however they are not a cure for Prostate Cancer. What’s next for these patients may include Alpha therapies attached to antibodies, which are quite effective and have longer efficacy when compared to other developing therapies. Nat Lenzo, MD explains the potential benefits of Alpha antibody therapy. Hear more.
Supported by Telix Pharmaceuticals as a service to medicine - Telix respects the independence of healthcare professionals and the views are those of the presenter.